Lancet Oncol 2024 Apr
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Related Questions
Or can we rely on NGS testing to determine eligible patients?
New answer by Medical Oncologist at IHA Hem Onc Consult (October 6, 2025)
Standard testing per IHC was required for entry onto the clinical trial that led to trastuzumab deruxtecan approval across cancer types.Meric-Bernstam et al., PMID 37870536Ple...